Next-Generation Antibody Therapeutics Market Share

Statistics for the 2023 & 2024 Next-Generation Antibody Therapeutics market share, created by Mordor Intelligence™ Industry Reports. Next-Generation Antibody Therapeutics share report includes a market forecast to 2029 and historical overview. Get a sample of this industry share analysis as a free report PDF download.

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Market Share of Next-Generation Antibody Therapeutics Industry

The market for next-generation antibody therapeutics is moderately competitive and consists of several major players. In terms of market share, a few of the major players are currently dominating the market. Some prominent players are acquiring other companies to consolidate their market positions across the globe, while others are launching new products. Some of the companies that are currently dominating the market are Amgen Inc., AstraZeneca Plc., Bayer AG, Biogen, Bristol-Myers Squibb Company, GlaxoSmithKline Plc., F. Hoffmann-La Roche Ltd., ImmunoGen Inc., Kyowa Hakko Kirin Co., Ltd., Pfizer Inc., Seagen Inc., and Xencor, Inc., among others.

Next-Generation Antibody Therapeutics Market Leaders

  1. AstraZeneca Plc.

  2. Bristol-Myers Squibb Company

  3. F. Hoffmann-La Roche Ltd.

  4. Pfizer, Inc.

  5. Seagen Inc.

*Disclaimer: Major Players sorted in no particular order

Concentration.png

Next-Generation Antibody Therapeutics Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)